BPC-157 vs TB-500: differences, research and why they are studied together
BPC-157 and TB-500 are the two names that come up most often in tissue-repair research, and they are frequently studied side by side. They are unrelated molecules: one is a short fragment of a stomach protein, the other is based on a protein that helps cells move. This guide compares where they come from, how they are thought to work and how strong the published evidence actually is.
At a glance
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Based on thymosin beta-4, a protein present in almost every human cell |
| Size | 15 amino acids (about 1.4 kDa) | Fragment: 7 amino acids; full thymosin beta-4: 43 amino acids (about 4.9 kDa) |
| Main proposed mechanism | Blood-vessel formation (VEGFR2), nitric-oxide pathways, fibroblast migration | Binding actin, the protein of the cell skeleton, which regulates cell migration |
| Notable property | Unusually stable, including in stomach acid | Its parent protein is one of the most abundant in cells |
| Evidence base | Mostly animal and cell studies; a few small human reports | Animal and cell studies; human trials only with full-length thymosin beta-4 |
| Approved as a medicine | No | No |
BPC-157
BPC stands for "Body Protection Compound". BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) corresponding to part of a larger protein isolated from human gastric juice. Most peptides break down quickly in acid and in the gut; BPC-157 is notably stable, which is why it has been studied both by injection and orally in animal models, and why an arginine salt form is used in oral research.
Much of the research comes from one group at the University of Zagreb, which has published on it since the early 1990s. In rodent models it has been studied in tendon, ligament, muscle and bone injuries, in damage to the stomach and intestinal lining, and in nervous-system injury. Proposed mechanisms include:
- Angiogenesis: activation and increased expression of VEGFR2, the main receptor for vascular growth factor, in endothelial cells.
- Fibroblast activity: in tendon cell cultures, increased cell survival, spreading and migration, linked to the FAK–paxillin pathway.
- Nitric oxide: interactions with the nitric-oxide system that regulates blood vessels.
Human data are very limited. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies, of which 35 were preclinical and only one was clinical: a small, uncontrolled retrospective report on knee pain. A two-person intravenous safety pilot has also been published. There are no completed controlled trials.
TB-500 and thymosin beta-4
Thymosin beta-4 (Tβ4) is a 43-amino-acid protein found in nearly all human cells. Its main known job is to bind single actin molecules (G-actin), keeping a reserve of actin that the cell can use to build its skeleton when it needs to move or change shape. Because cell migration is central to wound healing, Tβ4 has been studied for repair of skin, cornea and heart tissue.
- Wound healing: in rat models, Tβ4 increased the rate of skin wound closure, with more new blood vessels and collagen.
- Heart: in mice, Tβ4 promoted the migration and survival of heart cells and improved function after an induced heart attack.
- Eye and skin: full-length Tβ4 has been tested in human trials as eye drops and topical gels, without reaching approval.
What "TB-500" actually means
The name is used for two different things. Strictly, TB-500 refers to a synthetic 7-amino-acid fragment, Ac-LKKTETQ, which is the actin-binding region of Tβ4 (residues 17–23). In practice, some products sold as TB-500 contain the full 43-amino-acid Tβ4 instead. The two are not interchangeable: almost all of the published research, including every human trial, used full-length Tβ4, and the fragment has been much less studied on its own. Check the product description and its certificate of analysis to see which one you have.
Key differences
- Structure: BPC-157 has no relation to thymosin beta-4. They share no sequence and act on different targets.
- Mechanism: BPC-157 is mostly associated with blood-vessel growth and protection of tissues; Tβ4 with actin and the ability of cells to move into a damaged area.
- Gut: BPC-157's stability makes it the one studied for the stomach and intestine, and the one used in oral research.
- Research base: BPC-157's literature is large but comes largely from one research group; Tβ4 has been studied by many independent groups and has reached human trials, while the TB-500 fragment itself has not.
Why they are studied together
Because they act through different mechanisms, researchers combine them to see whether blood-vessel formation and cell migration together give a stronger or faster repair response than either alone, typically in tendon, muscle and wound models. Pre-mixed vials keep the ratio between the two fixed from one experiment to the next. Published controlled studies of the combination itself are scarce, so most of the rationale comes from the separate literature on each peptide.
Regulatory status
Neither BPC-157 nor TB-500 is approved as a medicine in the EU, the UK or the US, and both are on the World Anti-Doping Agency's prohibited list. They are sold for laboratory research only.
Handling
Both are supplied as lyophilised (freeze-dried) powder and behave like most research peptides: keep unopened vials in the freezer, away from light and moisture, and reconstituted solutions in the refrigerator. See our storage guide for details.
References
- Seiwerth S et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des 2018;24(18):1972–1989.
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011;110:774–780.
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 2017;95:323–333.
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025.
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021;27(4):8–13.
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005;11:421–429.
- Malinda KM et al. Thymosin β4 accelerates wound healing. J Invest Dermatol 1999;113:364–368.
- Bock-Marquette I et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432:466–472.